GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

It faces more than 1,800 lawsuits consolidated in federal court in Pennsylvania and new claims emerging weekly, according to ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk’s Ozempic gets Health Canada approval to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with T2D & CKD: Mis ...